Kathryn R Tringale, Anna Skakodub, Jacklynn Egger, Jordan Eichholz, Yao Yu, Daniel Gomez, Andreas Rimner, Bob Li, Yoshiya Yamada, Jessica Wilcox, Nelson Moss, Brandon S Imber, Natasha Rekhtman, Marina K Baine, Charles M Rudin, Luke R G Pike
PURPOSE: Small cell lung cancer (SCLC) often metastasizes to the brain and has poor prognosis. SCLC subtypes distinguished by expressing transcriptional factors ASCL1 or NEUROD1 have been identified. This study investigates the impact of transcription factor-defined SCLC subtype on incidence and outcomes of brain metastases (BMs). METHODS: Patients with SCLC with ASCL1 (A) and NEUROD1 (N) immunohistochemical expression status were identified and classified: (1) A+/N-, (2) A+/N+, (3) A-/N+, and (4) A-/N-...
April 2024: JCO Precision Oncology